Company Website:
http://www.mhtx.com
ALBUQUERQUE, N.M. -- (Business Wire)
Three months ago Manhattan Scientifics (OTCQB: MHTX) announced the
delivery of its 1st breakthrough cancer measurement
instrument to M.D. Anderson Cancer Center in Houston.
The Company's technology uses iron oxide nanoparticles and a technique
it calls Magnetic Relaxometry to locate and measure cancers with a
sensitivity that would provide a diagnosis years before other known
methods. It is generally believed that very early detection of cancers
may well lead to their early elimination prior to metastasis and growth.
http://www.cancer.org/treatment/understandingyourdiagnosis/advancedcancer/advanced-cancer-what-is-metastatic.
Last January the company executed an agreement to collaborate with M.D.
Anderson to advance, demonstrate and validate its breakthrough
technology which was developed by Edward R. Flynn, PhD.
Dr. Flynn is the founder and chief scientist of the company’s
subsidiary, Senior Scientific LLC whose research was funded by the NIH
over an 8 year period. Thereafter Manhattan Scientific undertook the
commercialization, management and financing to take the science from
"bench to bedside". The Company has recently engaged special FDA
consultants in order to accelerate regulatory approval.
Sara McKenzie, FDA specialist said, "PharmaDirections is a professional
consulting firm that has ushered some 22 pharmaceutical and medical
device companies, large and small, through the labyrinth of the FDA. We
have been retained to guide your project through the regulatory process
and are optimistic, with high expectations, to be successful within a
reasonable timeframe. "
Management believes its technology will emerge as the next important
evolutionary step in cancer diagnostics; the next step beyond X-ray,
sonography, MRI, CT, and PET scanning.
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com)
is located in New Mexico, New York and Montreal. It is focused on
technology transfer and commercialization of transformative technologies
in the nano medicine space. The company is presently developing
commercial medical prosthetics applications for its ultra-fine grain
metals and plans to commercialize the cancer research work and nano
medical applications developed by Senior Scientific LLC, a unit of the
Company.
Forward-looking statement
This press release contains forward-looking statements, which are
subject to a number of risks, assumptions and uncertainties that could
cause the Company's actual results to differ materially from those
projected in such forward-looking statements. Management at Manhattan
Scientifics believes that purchase of its shares should be considered to
be at the high end of the risk spectrum. Forward-looking statements
speak only as of the date made and are not guarantees of future
performance. We undertake no obligation to publicly update or revise any
forward-looking statements.
Contacts:
Manhattan Scientifics, Inc. PR & IR
Marvin Maslow, 917-923-3300
marvin@mhtx.com
or
Corporate
Advisory/PR
Fastnet Advisors:
Anthony Furey, 631-665-1234
mtfurey@fastnetadvisors.com
or
Hawk
Associates:
Frank Hawkins, 305-451-1888
f.hawkins@hawkassociates.com
or
European
Contact:
Herbert Strauss, +43-316-296-316
herbert
"at" eu-ir.com
Source: Manhattan Scientifics
© 2024 Canjex Publishing Ltd. All rights reserved.